Drug
Ramucirumab
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Anti-VEGF |
| Group | VEGF mAb |
| Mechanism of Action | Anti-VEGFR2 antibody |
| Half-life | 14 d |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing via vascular normalization and endothelial VEGFR2/AKT/DNA-PKcs blockade. Endothelial injury is not tumor-restricted, so the mechanism provides a clear rationale for increased vascular normal-tissue side-effects—bowel injury, ischemic colitis, GI perforation/fistula, and impaired healing—particularly where the field includes bowel or previously irradiated tissue, plus a theoretical worsening of radiation lung fibrosis (Hamdeh et al., Alimentary Pharmacology & Therapeutics, 2021, citing Hapani et al.; Makita et al., International Journal of Clinical Oncology, 2026).
Data on this page refer exclusively to patients treated with
Ramucirumab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
VEGF mAb group page.